Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.
about
MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated formIdentification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation.MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses.Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory studyTecemotide: an antigen-specific cancer immunotherapy.Development of the PANVAC-VF vaccine for pancreatic cancer.PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.Mucins help to avoid alloreactivity at the maternal fetal interface.Strategies used for MUC1 immunotherapy: human clinical studies.Carcinoembryonic antigen as a vaccine target.Amplification of MUC1 in prostate cancer metastasis and CRPC developmentMUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.Systemic genetic transfer of p21WAF-1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex.Progress in Vaccine Therapies for Breast Cancer.Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses.New Approaches in Immunotherapy for the Treatment of Lung Cancer.
P2860
Q28365593-5863E9EB-7062-4970-8966-0CE91A37941FQ30442906-DB7973D8-5361-4C97-8EF2-8772C7F9596EQ31051680-99F7C780-CE6A-403E-BA20-2C192AE81141Q34206162-D7AC4DC4-0091-4ABB-9ABC-2C3B611FD382Q34494018-7CB39F95-D23B-4ABC-95E9-7F3029221421Q34624117-949F28E9-C062-438A-90A0-52BB68302F67Q35886589-065F6A0E-1B5B-458B-8E9B-7DBC7CFB0240Q35886761-7E4EF8DC-479B-436C-AD46-2A1A5545B02BQ36383786-D2EC0506-765E-4CF9-811B-6A801056E3C2Q36764939-CAC27F5D-ECE2-4A65-B96B-A70C25EC7F0AQ36995323-00456643-002D-469C-9545-03C6C7F91D4EQ37259597-745FD9FA-2BAB-412E-A891-417223192037Q37259606-47E771D3-D5A5-40FB-BB81-AB4187E45CD3Q37696276-36AD43AD-CDB7-4E2C-B770-0B0A8451AA7DQ38091088-267AFBB1-43F2-4E36-A33C-4B2FE0F75A59Q39802340-95F3E806-C24A-474A-BE8F-824FBBFE57B4Q41353888-86500B3D-8B38-454B-B946-1BBE921C3AF9Q41636538-912F13C5-27DA-4357-ADCF-5AC10A6046A7Q41880426-40DF1BF1-29F5-4E66-BCB9-57687116604DQ45863333-6444BBDA-65B0-46EC-A8CB-07D38A6312E1Q48556381-860157DA-23E5-4DFD-87FA-2879EF264DB1Q51773605-355AC761-B6A6-40CB-BF0C-C3CAA2FDD4FEQ52871134-0059925C-0FA8-4A68-9047-1CE9695A7EA8
P2860
Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Presentation of MUC1 tumor ant ...... n taken Up by dendritic cells.
@en
type
label
Presentation of MUC1 tumor ant ...... n taken Up by dendritic cells.
@en
prefLabel
Presentation of MUC1 tumor ant ...... n taken Up by dendritic cells.
@en
P2093
P356
P1433
P1476
Presentation of MUC1 tumor ant ...... n taken Up by dendritic cells.
@en
P2093
P304
P356
10.1006/CIMM.1999.1512
P577
1999-06-01T00:00:00Z